• February 25, 2019
• 0

Novartis has acquired rights to TQJ230 from Akcea Therapeutics, a novel cardiovascular drug that could become first-in-class and has the potential to treat million of patients. TQJ230 is based on the...

• February 25, 2019
• 0

Roche and Spark Therapeutics have announced they are to enter a definitive merger agreement for Roche to fully acquire Spark for $4.3bn - the first company to gain approval for...

• February 14, 2019
• 0

With focus firmly fixed on the future, Johnson & Johnson have confirmed payment of $3.4bn for California-based Auris, a leader in the surgical robotics market. Auris Health is a privately...

• February 7, 2019
• 0

Sales of Merck Sharp & Dohme's immuno-oncology drug Keytruda grew a massive 66% year-on-year bringing in $2.15bn in the fourth quarter surpassing most analysts expectations.  Earlier in January MSD announced...

• February 6, 2019
• 0

Britain's largest drugmaker GlaxoSmithKline has announced its 2018 financial results, showing that the company is making progress in rebuilding its pharmaceutical pipeline despite competition from generics. However the company has also...

• February 5, 2019
• 0

GlaxoSmithKline has signed a wide-reaching deal worth up to £3.2bn with German pharma giant Merck KGaA for the rights to a new type of immunotherapy for various difficult-to-treat cancers. Both...

• February 3, 2019
• 0

Novartis have announced a 5% in net sales in 2018, bringing the total to $51.9bn. Growth was primarily driven by Cosentyx (secukinumab), the human IgG1k monoclonal antibody for the treatment of...

• February 1, 2019
• 0

Johnson & Johnson has joined the ranks of Novartis and Pfizer in gene therapy having been granted licenses for three eye disease programs from Meiragtx for $100m as well as...

• January 30, 2019
• 0

UK biotech managed to attract a record-breaking £2.2bn in investment last year according to a BioIndustry Association (BIA) report. The news essentially means that British firms were able to capture...

• January 29, 2019
• 0

London-based Smart Respiratory Products has developed a device for asthma sufferers that detects exacerbations before patients feel them. The company began work in 2016 in the aim to revolutionise asthma...